論文

国際誌
2022年6月13日

Neuropathology and emerging biomarkers in corticobasal syndrome.

Journal of neurology, neurosurgery, and psychiatry
  • Shunsuke Koga
  • ,
  • Keith A Josephs
  • ,
  • Ikuko Aiba
  • ,
  • Mari Yoshida
  • ,
  • Dennis W Dickson

93
9
開始ページ
919
終了ページ
929
記述言語
英語
掲載種別
DOI
10.1136/jnnp-2021-328586
出版者・発行元
BMJ PUBLISHING GROUP

Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical sensory loss and alien limb phenomenon. Corticobasal degeneration (CBD) is one of the most common underlying pathologies of CBS, but other disorders, such as progressive supranuclear palsy (PSP), Alzheimer's disease (AD) and frontotemporal lobar degeneration with TDP-43 inclusions, are also associated with this syndrome.In this review, we describe common and rare neuropathological findings in CBS, including tauopathies, synucleinopathies, TDP-43 proteinopathies, fused in sarcoma proteinopathy, prion disease (Creutzfeldt-Jakob disease) and cerebrovascular disease, based on a narrative review of the literature and clinicopathological studies from two brain banks. Genetic mutations associated with CBS, including GRN and MAPT, are also reviewed. Clinicopathological studies on neurodegenerative disorders associated with CBS have shown that regardless of the underlying pathology, frontoparietal, as well as motor and premotor pathology is associated with CBS. Clinical features that can predict the underlying pathology of CBS remain unclear. Using AD-related biomarkers (ie, amyloid and tau positron emission tomography (PET) and fluid biomarkers), CBS caused by AD often can be differentiated from other causes of CBS. Tau PET may help distinguish AD from other tauopathies and non-tauopathies, but it remains challenging to differentiate non-AD tauopathies, especially PSP and CBD. Although the current clinical diagnostic criteria for CBS have suboptimal sensitivity and specificity, emerging biomarkers hold promise for future improvements in the diagnosis of underlying pathology in patients with CBS.

リンク情報
DOI
https://doi.org/10.1136/jnnp-2021-328586
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35697501
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380481
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000810934900001&DestApp=WOS_CPL
ID情報
  • DOI : 10.1136/jnnp-2021-328586
  • ISSN : 0022-3050
  • eISSN : 1468-330X
  • PubMed ID : 35697501
  • PubMed Central 記事ID : PMC9380481
  • Web of Science ID : WOS:000810934900001

エクスポート
BibTeX RIS